Literature DB >> 20505499

Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study.

Martin Köbel1, Steve E Kalloger, Patricia M Baker, Carol A Ewanowich, Jocelyne Arseneau, Viktor Zherebitskiy, Soran Abdulkarim, Samuel Leung, Máire A Duggan, Dan Fontaine, Robin Parker, David G Huntsman, C Blake Gilks.   

Abstract

Reproducible diagnosis of ovarian carcinoma cell types is critical for cell type-specific treatment. The purpose of this study was to test the reproducibility of cell type diagnosis across Canada. Analysis of the interobserver reproducibility of histologic tumor type was performed among 6 pathologists after brief training in the use of modified World Health Organization criteria to classify ovarian carcinomas into 1 of 6 categories: high-grade serous, endometrioid, clear cell, mucinous, low-grade serous, and other. These 6 pathologists independently reviewed a test set of 40 ovarian carcinomas. A validation set of 88 consecutive ovarian carcinomas drawn from 5 centers was subject to local review by 1 of the 6 study pathologists, and central review by a single observer. Interobserver agreement was assessed through calculation of concordance and kappa values for pair-wise comparison. For the test set, the paired concordance between pathologists in cell type diagnosis ranged from 85.0% to 97.5% (average 92.3%), and the kappa values were 0.80 to 0.97 (average 0.89). Inclusion of immunostaining results did not significantly improve reproducibility (P=0.69). For the validation set, the concordance between original diagnosis and local review was 84% and between local review and central review was 94%. The kappa values were 0.73 and 0.89, respectively. With a brief training exercise and the use of defined criteria for ovarian carcinoma subtyping, there is excellent interobserver reproducibility in diagnosis of cell type. This has implications for clinical trials of subtype-specific ovarian carcinoma treatments.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20505499     DOI: 10.1097/PAS.0b013e3181e1a3bb

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  33 in total

1.  Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.

Authors:  Carlos Parra-Herran; Jordan Lerner-Ellis; Bin Xu; Sam Khalouei; Dina Bassiouny; Matthew Cesari; Nadia Ismiil; Sharon Nofech-Mozes
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

3.  Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Authors:  Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-23       Impact factor: 4.254

Review 4.  Better therapeutic trials in ovarian cancer.

Authors:  Michael A Bookman; C Blake Gilks; Elise C Kohn; Karen O Kaplan; David Huntsman; Carol Aghajanian; Michael J Birrer; Jonathan A Ledermann; Amit M Oza; Kenneth D Swenerton
Journal:  J Natl Cancer Inst       Date:  2014-03-13       Impact factor: 13.506

5.  Hesperidin inhibits ovarian cancer cell viability through endoplasmic reticulum stress signaling pathways.

Authors:  Jun Zhao; Yali Li; Jinfang Gao; Yinshan De
Journal:  Oncol Lett       Date:  2017-09-01       Impact factor: 2.967

Review 6.  Ovarian cancer : making its own rules-again.

Authors:  Elise C Kohn; Jean Hurteau
Journal:  Cancer       Date:  2012-12-11       Impact factor: 6.860

Review 7.  [Preneoplasias of ovarian carcinoma: biological and clinical aspects of different pathways of tumorigenesis].

Authors:  A Staebler
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

8.  Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions.

Authors:  Martin Köbel; Li Luo; Xin Grevers; Sandra Lee; Angela Brooks-Wilson; C Blake Gilks; Nhu D Le; Linda S Cook
Journal:  Int J Gynecol Pathol       Date:  2019-07       Impact factor: 2.762

9.  Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus.

Authors:  Bojana Djordjevic; Shannon Westin; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2012-12-01

10.  Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium.

Authors:  Catherine M Olsen; Christina M Nagle; David C Whiteman; Roberta Ness; Celeste Leigh Pearce; Malcolm C Pike; Mary Anne Rossing; Kathryn L Terry; Anna H Wu; Harvey A Risch; Herbert Yu; Jennifer A Doherty; Jenny Chang-Claude; Rebecca Hein; Stefan Nickels; Shan Wang-Gohrke; Marc T Goodman; Michael E Carney; Rayna K Matsuno; Galina Lurie; Kirsten Moysich; Susanne K Kjaer; Allan Jensen; Estrid Hogdall; Ellen L Goode; Brooke L Fridley; Robert A Vierkant; Melissa C Larson; Joellen Schildkraut; Cathrine Hoyo; Patricia Moorman; Rachel P Weber; Daniel W Cramer; Allison F Vitonis; Elisa V Bandera; Sara H Olson; Lorna Rodriguez-Rodriguez; Melony King; Louise A Brinton; Hannah Yang; Montserrat Garcia-Closas; Jolanta Lissowska; Hoda Anton-Culver; Argyrios Ziogas; Simon A Gayther; Susan J Ramus; Usha Menon; Aleksandra Gentry-Maharaj; Penelope M Webb
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.